• Home
  • News
  • An Interview with MiraxBioPharma’s CEO

An Interview with MiraxBioPharma’s CEO

Brand transformation — first-hand account

A major interview with Vadim Drukh, General Director of MiraxBioPharma JSC, was published on one of the leading industry platforms – pharmvestnik.ru. The dialogue touched upon the Company’s rebranding, strategic directions, and pharmaceutical market evolution. The conversation was both engaging and candid — we invite you to read it.

More news:

МБФ на Форуме «Вузовская наука. Инновации‑2026»

MBP at the Forum “University Science. Innovations‑2026”
Мы приняли участие в 26-м Аптечном саммите

We attended the 26th Pharmacy Summit
Встречаемся на SobMaExpo!

Meet us at SobMaExpo!
Мы подтвердили высочайший уровень системы менеджмента качества

We have confirmed the highest level of our quality management system

Contact us

Select a service*

Pharmacovigilance

MiraxBioPharma is committed to ensuring the quality and safety of its products and pays special attention to collecting and analyzing information about adverse reactions and complaints associated with the use of our products.

If you become aware of any adverse reactions to the medicinal product Cezarox® Epi or of a lack of therapeutic effect, please report it via email at: adversareaction@drugsafety.ru or by phone: +7 (800) 777-86-04.

If you become aware of any adverse reactions to other MiraxBioPharma medicinal products or of a lack of therapeutic effect, please report it via email at: GVP@mbpharma.ru, by phone: +7 (495) 721-20-58 or by filling out the electronic form below

Adverse reaction reporting form
Specify gender*
Suspected medicinal product information
Reporter information

Preferred method of contact*
We use cookies

Используя этот сайт, Вы даете Согласие на сбор и обработку Ваших персональных данных, в том числе с привлечением сторонних сервисов и с применением cookie-файлов и средств веб-аналитики, на условиях, изложенных в Personal Data Processing Policy.